News & Views
Sequencing Service Supports SARS-CoV-2 Testing Labs
Mar 21 2021
A service for Whole Genome Sequencing of SARS-CoV-2, developed to enable the UK government’s Test-To-Release scheme, is available from precision medicine and liquid biopsy developers Nonacus. Assay development for the new service was funded by a grant from Innovate UK.
Government regulations, recently announced, set out the minimum standards that private sector providers must meet for SARS-CoV-2 tests for people arriving in England. All international arrivals to the UK are required to take a test on day 2 and day 8 of their quarantine period for variant surveillance. Day 2 samples shown to be positive from qRT-PCR testing will have the SARS-CoV-2 genomes sequenced to look for novel variants. Nonacus’ new service will support this scheme and enable monitoring of the disease.
During the pandemic, Nonacus developed a complete SARS-CoV-2 testing workflow and Whole Genome Viral Sequencing library approach with nanopore sequencing.
Chris Sale, CEO of Nonacus, said: “We are proud to have developed this service and support the government’s test-to-release scheme. Our method will provide a faster, lower cost offering for Whole Genome Viral Sequencing, which will be key in identifying and monitoring variants. We look forward to supporting laboratories undertaking SARS-CoV-2 testing, as well as aiding public health institutions in their surveillance of the virus.”
Further information online
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia